Seaport Therapeutics doses first patient in anxiety disorder trial
Tweet Send to a Friend
Seaport Therapeutics (Nasdaq: SPTX), a founded entity of PureTech Health (LSE: PRTC), announced that the first patient has been dosed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




